Economic Analysis of Generic Substitution of Antihypertensive Medicines in Moldova

Home » Projects » Economic Analysis of Generic Substitution of Antihypertensive Medicines in Moldova

Presentation of Dr Jari Kempers on Economic Analysis of Generic Substitution of Antihypertensive Medicines in Moldova. How much would a mandatory generic drug substitution policy save? What are the impacts on the National Health Insurance Company’s (CNAM) drug reimbursement budget and patients’ co-payments?

Substitution of original medicines with their generic equivalents is a key cost-containment strategy used in most of the countries in Europe. In Moldova, the raising drug reimbursement costs pose challenges to the financing of the healthcare system. However, an effective generic substitution policy is not in place yet.

This policy brief assesses the potential cost-savings generated by mandatory generic substitution of antihypertensive (AHT) medicines in Moldova and predicts the impacts on the National Health Insurance Company (CNAM) reimbursement budget and patients’ co-payments. The objective of this policy brief is to open policy discussion with this practical example of AHT drugs.

Health economist (PhD), Dr Jari Kempers

About the author

Dr Jari Kempers is a senior health economist (PhD) and consultant. He founded Qalys Health Economics in 2007. He helps healthcare policymakers and programme managers to make better plans and decisions by providing technical assistance and strategic advice on health economics and health financing topics.

Newsletter

Stay up to date. Get health economics news and tips for your work.

You can unsubscribe at any time